Purpose: Vascular targeted photodynamic therapy with TOOKADÒ is a new therapeutic option for localized prostate cancer management. The objectives of this study were to assess the feasibility of radical prostatectomy after vascular targeted photodynamic therapy and describe functional and oncologic outcomes. Materials and Methods: We retrospectively included in study 45 patients who underwent salvage radical prostatectomy after vascular targeted photodynamic therapy for recurrent prostate cancer at a total of 14 surgical centers in Europe between October 2008 and March 2017. Of the 42 radical prostatectomies performed 16 were robot-assisted, 6 were laparoscopic and 20 were open surgery. Primary end points were morbidity and technical difficulties. Secondary end points were early and intermediate postoperative functional and oncologic outcomes. Results: Median operative time was 180 minutes (IQR 150-223). Median blood loss was 200 ml . According to the surgeons the surgery was easy in 29 patients (69%) and difficult in 13 (31%). Nerve sparing was feasible in 14 patients (33%). Five postoperative complications (12%) were found, including 2 Clavien I, 2 Clavien II and 1 Clavien IIIB complications. Of the cases 13 (31%) were pT3 and 21 (50%) were pT2c. Surgical margins were positive in 13 patients (31%). Prostate specific antigen was undetectable at 6 to 12 months in 37 patients (88%). Nine patients underwent complementary radiotherapy. Four patients had final prostate specific antigen greater than 0.2 ng/ml at a median followup of 23 months . At 1 year 27 patients (64%) were completely continent (no pads) and 10 (24%) had low incontinence (1 pad). Four patients (11%) recovered potency without treatment and 23 (64%) recovered potency with appropriate treatment. Conclusions: Salvage radical prostatectomy after vascular targeted photodynamic therapy treatment was feasible and safe without difficulty for most of the surgeons. The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
Purpose: Vascular targeted photodynamic therapy with TOOKADÒ is a new therapeutic option for localized prostate cancer management. The objectives of this study were to assess the feasibility of radical prostatectomy after vascular targeted photodynamic therapy and describe functional and oncologic outcomes. Materials and Methods: We retrospectively included in study 45 patients who underwent salvage radical prostatectomy after vascular targeted photodynamic therapy for recurrent prostate cancer at a total of 14 surgical centers in Europe between October 2008 and March 2017. Of the 42 radical prostatectomies performed 16 were robot-assisted, 6 were laparoscopic and 20 were open surgery. Primary end points were morbidity and technical difficulties. Secondary end points were early and intermediate postoperative functional and oncologic outcomes. Results: Median operative time was 180 minutes (IQR 150-223). Median blood loss was 200 ml (IQR 155-363). According to the surgeons the surgery was easy in 29 patients (69%) and difficult in 13 (31%). Nerve sparing was feasible in 14 patients (33%). Five postoperative complications (12%) were found, including 2 Clavien I, 2 Clavien II and 1 Clavien IIIB complications. Of the cases 13 (31%) were pT3 and 21 (50%) were pT2c. Surgical margins were positive in 13 patients (31%). Prostate specific antigen was undetectable at 6 to 12 months in 37 patients (88%). Nine patients underwent complementary radiotherapy. Four patients had final prostate specific antigen greater than 0.2 ng/ml at a median followup of 23 months (IQR 12-36). At 1 year 27 patients (64%) were completely continent (no pads) and 10 (24%) had low incontinence (1 pad). Four patients (11%) recovered potency without treatment and 23 (64%) recovered potency with appropriate treatment. Conclusions: Salvage radical prostatectomy after vascular targeted photodynamic therapy treatment was feasible and safe without difficulty for most of the surgeons. August 29, 2018 . The corresponding author certifies that, when applicable, a statement(s) has been included in the manuscript documenting institutional review board, ethics committee or ethical review board study approval; principles of Helsinki Declaration were followed in lieu of formal ethics committee approval; institutional animal care and use committee approval; all human subjects provided written informed consent with guarantees of confidentiality; IRB approved protocol number; animal approved project number.
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No direct or indirect commercial incentive associated with publishing this article. The current treatment strategies for localized PCa are AS or radical therapies such as RP. On 1 hand AS might represent a risk of progression 3 and on the other hand radical therapies induce significant morbidity with a negative impact on quality of life. 4 Vascular targeted photodynamic TOOKADÒ therapy enables focal ablation resulting from rapid occlusion of tumor vascularization within a few minutes of treatment. This treatment was well tolerated in a randomized study comparing VTP to AS. 5 Therefore, VTP appears to be an alternative in patients who wish to be treated with a limited risk of side effects. 5, 6 Despite studies showing short-term effectiveness of focal treatments in select patients and tumors 5, 6 focal therapy needs to be thoroughly studied. 7, 8 A major question is to assess the impact of focal therapies on subsequent therapeutic options in case of failure. 9, 10 Therefore, the aim of this study was to assess the feasibility, safety and efficacy of salvage RP of recurrent PCa after TOOKAD VTP.
MATERIAL AND METHODS
Study Design
This retrospective study included all patients who underwent salvage RP after VTP of recurrent PCa at a total of 14 surgical centers in Europe between October 2008 and March 2017. These patients were initially included in 1 of the 2 phase II nonrandomized studies PCM201 (ClinicalTrials.gov NCT00707356) and PCM203 (ClinicalTrials.gov NCT00975429) or in the phase III European randomized study PCM301 (ClinicalTrials.gov NCT01310894). This study received Institutional Review Board approval (IRB No. CERU 2018/007).
Data Collection
For each patient data were prospectively extracted, including age at the time of VTP and pre-VTP biopsy data. Control biopsies were systematically performed at 6 months in patients in phase II studies, and at 12 and 24 months in patients in phase III studies. Subsequent biopsies were performed if PSA progression was confirmed by 2 successive tests or there was clinical progression on digital rectal examination. Progression was defined as a shift from the low risk to the intermediate or high risk prognosis group according to the D'Amico classification. We used the contemporary 2015 ISUP (International Society of Urological Pathology) PCa grading system, including group 1dGleason 3 þ 3, group 2dGleason 3 þ 4, group 3dGleason 4 þ 3, group 4dGleason 8 and group 5dGleason 9 or 10. 11 We also recorded whether a second VTP procedure was performed prior to prostatectomy.
Data were collected retrospectively, including time between VTP and prostatectomy, operative data (blood loss, transfusion, operative time, conversion, observed surgical difficulties and NS extent) and perioperative outcomes (urethral catheterization time, hospital stay and postoperative complications). Complications were graded according to the Clavien-Dindo classification. 5 Surgical difficulties were classified as easy or difficult. The nature of the surgical difficulties and perioperative complications were described retrospectively.
Short-term oncologic outcomes were assessed by pathological analysis of the whole mount specimen. Midterm oncologic outcomes were assessed by PSA measurements and subsequent additional oncologic treatment. Biochemical recurrence was defined as PSA greater than 0.2 ng/ml measured twice successively. 1 Complete continence was defined as absence of the need for pads. Low continence was defined as effort leakage with the need for 1 pad per day. Medium continence was defined as the need for 2 pads per day. Complete incontinence was defined as permanent urinary leakage with the need for more than 2 pads per day. Erectile function was defined as the possibility of sexual intercourse without treatment, the possibility with treatment or no possibility of sexual intercourse.
Statistical Analysis
Quantitative variables are shown as the median and IQR, and were compared between groups by the Wilcoxon test. Qualitative variables are shown as the frequency and percent, and were compared by the Fisher exact test. Significance was considered at p <0.05. Statistical analysis was done with R, version 3.1.0 (https://www.r-project.org/).
RESULTS
We analyzed the files of 313 patients who underwent VTP during 1 of the 2 phase II nonrandomized studies PCM201 and PCM203 or in the phase III European randomized study PCM301.
Of all patients treated with VTP 45 (19%) underwent subsequent RP of recurrent PCa after VTP. Three patients were excluded from analysis because of insufficient data. Data on 42 patients were analyzed with a median post-prostatectomy followup of 23 months (IQR 12-36). Table 1 lists patient characteristics before VTP and prostatectomy. Median age at RP was 65 years (IQR 61-67). Median prostate volume before VTP was 35 ml (IQR 30-46). Median PSA before RP was 5.9 ng/ml (IQR 3.2-7.9).
Median time between VTP and prostatectomy was 17 months (IQR 12-36). Five patients (12%) underwent a second VTP procedure. Of the 42 prostatectomies 16 were robot-assisted, 6 were laparoscopic and 20 were open. No conversion was necessary during laparoscopic or robot-assisted surgery. According to the postoperative report the surgery was considered easy in 29 patients (69%) and difficult in 13 (31%). In most cases the reported difficulty was due to lateral fibrosis during dissection of the nerve bundles on the VTP treated lobe. The other difficulty was linked to posterior fibrosis with adherence to the rectum, leading in 2 cases to significant difficulty in separating the rectum from the posterior face of Denonvilliers fascia. There were no rectal injuries reported during the procedures or postoperatively. Bilateral NS was feasible in 10 patients (24%) and unilateral NS was feasible in 4 (10%). There was no NS in 28 cases (67%). Most surgeons reported that NS on the nontreated side was not more difficult than usual. On the treated side preservation was done carefully and bipolar forceps instead of clips were more often needed because of tissue adherence. Usually the surgeons began with the nontreated lobe, which was considered easier.
Median urethral catheterization time was 7 days (IQR 7-8). Median hospital stay was 7 days (IQR 5-8).
No perioperative mortality was reported. Five postoperative complications (12%) were found, of which 2 were Clavien I (1 transient ileus and 1 wound infection), 2 were Clavien II (febrile urinary tract infections) and 1 was Clavien IIIB (an accidental ureteral section which occurred during pelvic lymphadenectomy of open prostatectomy and required direct reanastomosis and 18 days of urethral catheterization). Table 3 lists oncologic outcomes. Surgical margins were positive in 13 patients (31%), including on the treated side in 7 (54%). Only 1 of the 14 patients (7%) who underwent NS had positive surgical margins. Two patients (7%) had positive lymph nodes. PSA was less than 0.2 ng/ml at 6 to 12 months in 37 patients (88%). Four patients had a biological recurrence, 1 had metastatic disease (neuroendocrine component), 9 underwent complementary radiotherapy, 6 had positive surgical margins (including 3 with postoperative PSA greater than 0.2 ng/ml), 2 had positive lymph nodes, 2 had biological recurrence and 1 had metastatic extension (neuroendocrine contingent).
Of the patients 37 (88%) were continent, including 27 (64%) who did not need any pads and 
DISCUSSION
In September 2017 TOOKAD padeliporfin obtained marketing authorization from the European CHMP (Committee for Medicinal Products for Human Use) as first intention in patients with low risk prostate cancer and a 10-year life expectancy. In this setting VTP has demonstrated safety and efficacy compared to active surveillance. 5 In our study we included all patients in the study by Lebdai et al. 12 Our findings confirm that performing prostatectomy after VTP was safe and feasible in all cases.
Contrary to other series of salvage prostatectomy following focal therapy, surgery after VTP seems feasible. 9, 13 Surgeons reported that lateral fibrosis made nerve bundle dissection difficult on the VTP treated side. They also reported posterior fibrosis with adherence to the rectum, leading to a pass in rectum fibers in 2 cases. However, despite these difficulties no rectal injuries and no anastomotic strictures occurred.
14 Operative time and blood loss were similar to those of primary prostatectomy. 15, 16 Hospital stay and urethral catheterization time were standard. 16 Contrary to the previous series, 12 we did not find any significant association between bilateral treatment and surgical difficulties. A second concern regards oncologic outcomes. We noted a relatively high positive lymph node rate in this cohort, for which lymphadenectomy is usually not recommended because of a less than 7% risk. Some groups have reported similar rates in low risk cohorts. 17, 18 The 31% incidence of positive surgical margins was similar to the literature 5 but also higher than what might be expected in this select group of patients with low risk prostate cancer, which was defined as PSA 10 ng/ml or less, T2a and Gleason score 7 (3 þ 4) or less. This could be explained by the frequency of bilateral involvement and extracapsular extension, and might be due to the fact that no second biopsy was mandatory at study inclusion. This underlines the need to improve our initial staging by using more precise tools such as MRI guided biopsies. 19, 20 As preRP MRI was only available at a few centers, we were unable to include imaging data. Therefore, some cases might have been under staged or graded. One case is particularly obvious. Metastasis developed after RP despite the fact that only 4 months had passed between VTP and surgery. Final pathology revealed neuroendocrine differentiation, which had not been diagnosed on biopsy. Of course, inaccurate staging of the initial tumor is a hindrance to appropriate patient selection for focal therapies and active surveillance. We are confident that contemporary diagnostics aid in better treatment recommendations in individual patients.
In the treated parts anatomopathological examination of the prostate revealed fibrous changes as well as zones of coagulation necrosis.
Currently there has been no difference in oncologic control and recovery of continence or erectile function among surgical approaches. 21 However, we may ask whether robot-assisted surgery may ease NS. Only 2 patients underwent bilateral NS during open surgery, although NS was not associated with positive margins. NS seemed technically feasible even on the treated side in 14 patients. Only 1 of these patients subsequently had a positive surgical margin. The rate of surgical margins and the quality of NS depend on surgeon experience, particularly with robot-assisted surgery. No decision was made to perform an open, laparoscopic or robotic approach based on stage, morbidity or patient age. Table 6 shows that our continence results were similar to those of primary prostatectomy 22 and salvage prostatectomy 23 in the literature. According to Ficarra et al the 12-month urinary continence rate ranged from 48% to 93.7% after primary prostatectomy. 16 In our series 1 of the patients with incontinence had a followup of only 3 months after prostatectomy, which was not enough to reach definitive continence status. In the same way the potency rate was similar after primary prostatectomy. Carlsson et al reported potency in 44% of men with appropriate treatment after prostatectomy of very low risk PCa. 22 Recently a prospective study reported 70% to 75% erectile dysfunction in cases of open and robot assisted primary RP. 24 If we focus on the results of salvage prostatectomy, our results seem to be better. 9, 13, 14, 25, 26 We acknowledge limitations of this study, including the small number of patients, the retrospective aspect of our data, the high number of centers, the fact that no standardized questionnaires were used to assess functional outcomes and the relatively short followup. Surgical difficulty was evaluated by the surgeons who operated on the patients based on their notes. Although there is a risk of recall bias, we believe that this approximate assessment was reliable because the procedures were recent and not that many patients had this indication.
However, to our knowledge this is the largest salvage RP series after VTP to date.
Given the uncertainty of the effect of radiotherapy on treated tissues, surgery was chosen in all cases as salvage treatment but other options such as radiotherapy should be explored.
CONCLUSIONS
Salvage RP after TOOKAD vascular targeted photodynamic therapy was feasible, safe and efficient to Table 6 . Functional outcomes in present series and data from literature treat locally recurrent PCa in most cases. Short-term oncologic and functional outcomes were comparable to those of regular radical prostatectomy but longterm followup is needed for oncologic outcomes.
EDITORIAL COMMENTS
When patients are considering partial gland ablation for localized prostate cancer, they frequently ask whether radical prostatectomy is a viable option should treatment fail or cancer recur in the future. Pierrard et al help answer this important question by describing their experience with 45 salvage radical prostatectomies following focal VTP with TOOKAD. The surgeons were asked for their subjective opinion whether the case was easy or hard and the majority of cases were thought to be straightforward with minimal blood loss and reasonable operative time. Furthermore, there were no significant adverse events or aborted operations. The functional outcomes are good with two-thirds of the patients pad-free, making salvage RP after VTP a viable option for many patients.
Overall oncologic outcomes were good but there is some concern regarding the pattern of failure. For example, positive margins in 31% of patients were equally likely to occur on the VTP treated side as the untreated side. Also, 2 patients had positive lymph nodes. This hints at suboptimal pretreatment risk assessment, which I suspect was related to the low rates of confirmatory biopsy and MRI before VTP.
I recognize the challenges of standardizing workup and risk assessment across 10 years and 14 surgical sites but I think that we need to be more conservative when offering partial gland ablation for prostate cancer. At our site we require MRI and fusion biopsy with systematic cores prior to inclusion in focal therapy trials.
Nathan Perlis
Urologic Oncology Sprott Department of Surgery University Health Network Princess Margaret Cancer Centre University of Toronto Toronto, Ontario, Canada
As shown in this study, the management of recurrent PCa after ablative therapy represents an up-to-date concern (reference 5 in article).
1,2 PCa progression after vascular targeted photodynamic therapy has been described in up to 28% of patients with about 50% still having PCa at 2 years (reference 5 in article).
Rather than be considered a definitive treatment, based on these midterm outcomes vascular targeted photodynamic therapy seems to be a way to defer it.
A patient eligible for vascular targeted photodynamic therapy should be aware of the burden of the ablative procedure itself and of bothersome observation, likewise active surveillance. Followup is yet undefined (with variable scheduling in this study) and possibly biased from the nonquantifiable effect of vascular targeted photodynamic therapy on the prostate. Beyond these considerations it is important to define whether previous tissue preserving treatments may bother a salvage approach compared with the same surgery in a na€ ıve surgical field, as in the case of AS failure.
Pierrard et al outline salvage RP oncologic safety with reasonable functional outcomes from skilled surgeons. However, what if those patients initially at low risk were surgically treated without previously handling the prostate gland? Results from recent robotic series show a 98.5% continence rate and a 86.7% potency rate. 2 Provided that the longterm survival benefit is far to be attained in a low risk cohort, further insights into the recurrence-free and progression-free end points are required to balance the advantages of vascular targeted photodynamic therapy with the risk of feasible but still challenging and impaired salvage RP.
